Sociedad Americana de Hirudoterapia

Neurocoagulation from a Mechanistic Point of View in the Central Nervous System

Review published in Seminars in thrombosis and hemostasis (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosShavit-Stein E et al. · Seminars in thrombosis and hemostasis, 2022

Abstract

Coagulation mechanisms are critical for maintaining homeostasis in the central nervous system (CNS). Thrombin, an important player of the coagulation cascade, activates protease activator receptors (PARs), members of the G-protein coupled receptor family. PAR1 is located on neurons and glia. Following thrombin activation, PAR1 signals through the extracellular signal-regulated kinase pathway, causing alterations in neuronal glutamate release and astrocytic morphological changes. Similarly, the anticoagulation factor activated protein C (aPC) can cleave PAR1, following interaction with the endothelial protein C receptor. Both thrombin and aPC are expressed on endothelial cells and pericytes in the blood-brain barrier (BBB). Thrombin-induced PAR1 activation increases cytosolic Ca2+ concentration in brain vessels, resulting in nitric oxide release and increasing F-actin stress fibers, damaging BBB integrity. aPC also induces PAR1 activation and preserves BBB vascular integrity via coupling to sphingosine 1 phosphate receptors. Thrombin-induced PAR1 overactivation and BBB disruption are evident in CNS pathologies. During epileptic seizures, BBB disruption promotes thrombin penetration. Thrombin induces PAR1 activation and potentiates N-methyl-D-aspartate receptors, inducing glutamate-mediated hyperexcitability. Specific PAR1 inhibition decreases status epilepticus severity in vivo. In stroke, the elevation of brain thrombin levels further compromises BBB integrity, with direct parenchymal damage, while systemic factor Xa inhibition improves neurological outcomes. In multiple sclerosis (MS), brain thrombin inhibitory capacity correlates with clinical presentation. Both thrombin inhibition by hirudin and the use of recombinant aPC improve disease severity in an MS animal model. This review presents the mechanisms underlying the effects of coagulation on the physiology and pathophysiology of the CNS.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsBlood-Brain BarrierEndothelial CellsGlutamic AcidHumansReceptor, PAR-1Thrombin

Resumen

Coagulation mechanisms are critical for maintaining homeostasis in the central nervous system (CNS).

Por qué esto importa para la hirudoterapia

This review examines how coagulation proteases—particularly thrombin and activated protein C—influence central nervous system physiology and pathophysiology through protease-activated receptor-1 (PAR1) signaling, with relevance to epilepsy, stroke, and multiple sclerosis. The abstract reports that thrombin inhibition by hirudin, along with recombinant activated protein C, improved disease severity in a multiple sclerosis animal model, situating this finding within ASH's domain of thrombin-modulating agents. The key caveat is that this is a review (per publication types) drawing on preclinical animal evidence; the hirudin observation is one finding among many, with no clinical data, no direct hirudotherapy application, and no mention of leeches anywhere in the abstract.

Citación

Neurocoagulation from a Mechanistic Point of View in the Central Nervous System

Shavit-Stein E et al. · Seminars in thrombosis and hemostasis, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.